ArticleMolecular therapy. Advances2026
Vortex-actuated pre-enrichment accelerates human regulatory T cell sorting and improves early fitness.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell selection is critical for regulatory T cell (Treg) therapy manufacturing. Pre-enrichment can reduce sorting time, yet data comparing different methods remain scarce. Highway1, a Good Manufacturing Practice (GMP)-compliant cell sorter, separates cells using transient vortices (i.e., vortex-actuated cell sorting [VACS]), which avoids exposure to magnetic nanoparticles and may improve cell viability compared to immunomagnetic separation (IMS). We compared VACS with IMS enrichment before sorting for human Tregs. Tregs were sorted from peripheral blood mononuclear cells isolated from donor leukocyte cones directly using the Highway1 (DP), CD4+CD25+ VACS enrichment then VACS (VP), or CD25+ IMS positive selection then VACS (25MP), and expanded with anti-CD3+/CD28+ stimulation beads, IL-2, and rapamycin. VP, 25MP, and DP produced Tregs of comparable purity. VP reduced sorting time but decreased yield compared to DP. VP resulted in fewer late apoptotic and hypoproliferative, IL-2 hyporesponsive cells, and generated Tregs that expanded more than 25MP. Phenotypic markers and suppression function did not differ after 21 days of expansion. CD4+CD25+ VACS enrichment reduced the time needed for Treg sorting compared to direct VACS and generated Tregs that expanded more than those enriched by CD25+ IMS selection, supporting adoption of a single-platform, closed VACS workflow and justifying validation at GMP scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.